ALPMY News and Press, Astellas Pharma Inc. ADR From 09/18/20

TOKYO and BOTHELL, Wash. , Sept. 18, 2020 /PRNewswire/ --  Astellas Pharma Inc.  (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") and Seattle Genetics, Inc . (Nasdaq:SGEN) today announced that a phase 3 trial of PADCEV ® (enfortumab vedotin-ejfv) met ...

Company Overview Frequency Therapeutics ( FREQ ) is a clinical-stage company targeting sensorineural hearing loss ((SNHL)). SNHL, currently, affects more than 40M people in the US and that number is expected to grow by 20% over the next decade, representing a substantial domestic market. The...

Quick Take Virios Therapeutics ( VIRI ) has filed to raise $34.5 million in an IPO of its common stock, according to an S-1 registration statement . The company is developing a drug treatment for fibromyalgia, a nerve pain condition. VIRI has generated interesting early stage efficacy r...

BioMarin ( BMRN ) received a complete response letter or CRL for their hemophilia A gene therapy Valrox last week. As a result, the earliest commercial launch is now in 2023. Audentes ( ALPMF ) provided an update on their please 3 neuromuscular ASPIRO clinical trial indicating a third pati...

Original post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha Read more ...

Astellas Pharma Inc (ALPMF) Q1 2021 Earnings Conference Call August 04, 2020 3:00 AM ET Company Participants Naoki Okamura – Representative Director and Executive Vice President Mike Kitagawa – Senior Vice President of Development Project Management Yukio Matsui &#x...

The following slide deck was published by Astellas Pharma Inc. in conjunction with their 2020 Q1 earnings Read more ...

TOKYO , July 22, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa , Ph.D., "Astellas") today announced it has been awarded a grant from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH) in the U.S. ...

Quick Take iTeos Therapeutics ( ITOS ) intends to raise $151 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is developing a range of treatments for various cancers, including solid tumors. ITOS is pursuing treatments for...

Quick Take iTeos Therapeutics ( ITOS ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The company is a clinical stage biopharma firm advancing a pipeline of immuno-oncology drug candidates for treating solid tumors and other can...